FDA Approval Summary: Sotorasib for KRAS G12C-Mutated Metastatic NSCLC. Nakajima EC, Drezner N, Li X, Mishra-Kalyani PS, et al. Clin Cancer Res 2022;28:1482-1486.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Nakajima EC, Drezner N, Li X, Mishra-Kalyani PS, et al. FDA Approval Summary: Sotorasib for KRAS G12C-Mutated Metastatic NSCLC. Clin Cancer Res 2022;28:1482-1486.
PMID: 34903582